Sábado, 20 Octubre, 2018

Palace: People in Dengvaxia snafu will pay

Senator Joseph Victor “JV” Ejercito Senator Joseph Victor “JV” Ejercito
Cris De Lacerda | 04 Diciembre, 2017, 09:22

"Approval is only given for the Dengvaxia to be used in Phase IV clinical trials aimed at getting more information on the safety of the vaccine".

Sanofi executives also stressed that the drug would still be beneficial to majority of Filipinos, given that nine out of ten of them aged nine to 14 years old had already been infected with dengue but not all of them were hospitalized for the illness, given that three-fourths of dengue cases were asymptomatic.

The sweeping tax overhaul that passed the U.S. Senate on Saturday contains the Republicans' biggest blow yet to former President Barack Obama's healthcare law, repealing the requirement that all Americans obtain health insurance.

DOH posted on its website that the dengue vaccine helps protect children against dengue caused by dengue virus serotypes 1, 2, 3 and 4.

The Department of Health has suspended its landmark public vaccination program following Sanofi's announcement.

French pharmaceutical giant Sanofi Pasteur on Wednesday admitted clinical data showed Dengvaxia - the first licensed dengue vaccine - could make the disease worse in people who had not previously been infected with the virus.

Dengue, according to the World Health Organization, is a mosquito-borne "pandemic-prone viral disease" which causes severe flu-like symptoms.

The France-based manufacturer of dengue vaccine Dengvaxia, on November 29 disclosed that the vaccine poses risks to those who had not been previously infected with the dengue virus.

"We need a database to identify the 70,000 affected children and know where they are exactly located in order for the government to keep track of their health and prepare the needed resources and logistics that will allow for quick and appropriate medical responses, if needed".

"Severe dengue" as used by Sanofi means fever for two days, a drop in platelet count, hematoma, among other symptoms.

"We see fewer hospitalisation and fewer cases of severe dengue among those who were vaccinated against those who received a placebo", she said.

The World Health Organisation, though, defines "severe dengue" as "a potentially deadly complication due to plasma leaking, fluid accumulation, respiratory distress, severe bleeding, or organ impairment".

Dr Ng said said Dengvaxia has prevented 65.5 per cent of dengue infections, saved four of five from incurring huge hospital bills, and averted nine in 10 cases of severe dengue.

Spokesman Eric Tayag said the agency was "prepared for a worst-case scenario" and that children who have received it are being "followed up for adverse effects following immunisation".

Peing said she would not recommend Dengvaxia for those who have never been infected.